Acanthosis nigricans - I-Acanthosis Nigricans
☆ AI Dermatology — Free Service
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Ixhaphakile kubantu abatyebileyo kakhulu.
relevance score : -100.0%
ReferencesAcanthosis nigricans ibonakala njengokutshintsha kombala wesikhumba semeko ephantsi. Ihlala ivele kwimiphetho yesikhumba efana neentamo, amakhwapha, kunye ne‑groin, ibonakala njengamabala amnyama anemiphetho engacacanga. Le meko idla ngokunxulunyaniswa nesifo seswekile kunye nokunganyanzelekanga kwe‑insulin, kodwa kwiimeko ezinqabileyo, inokukhomba umngcipheko wengxaki zangaphakathi emzimbeni. Inokubonakala ngenxa yemicimbi yehomoni okanye ngenxa yokuthatha amayeza athile anjengee‑steroids kunye neepilisi zolawulo lokuzalwa.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans is a cutaneous manifestation of an underlying condition. It usually develops in skin folds, such as the back of the neck, axilla, and groin, where it presents as velvety hyper-pigmented patches with poorly defined borders. Acanthosis nigricans is most commonly associated with diabetes and insulin resistance, but rarely it can be a sign of internal malignancy. It can also occur with hormone disorders or with the use of certain medications like systemic glucocorticoids and oral contraceptives.
Acanthosis nigricans (AN) yimeko yolusu eqhelekileyo edityaniswe kwimiba eyahlukeneyo yezempilo, njengokunganyamekeli kwe‑insulin, isifo seswekile, ukutyeba, umhlaza othile, iingxaki zehomoni, kunye nokusabela kumayeza. Ukunyanga i‑AN kugxile ekujongeni iimeko zempilo ezisisiseko. Ekuqaleni, oogqirha bahlola iimpawu ze‑insulin resistance syndrome, okubandakanya ukutyeba, i‑cholesterol ephezulu, uxinzelelo lwegazi oluphezulu, kunye neswekile yoHlobo lwe‑2. Oogqirha bahlala becebisa i‑topical retinoids njengokhetho lokuqala lonyango, olunokunceda ekuqiniseni isikhumba. Nangona kunjalo, abakwazi ukujongana ngokupheleleyo nobumnyama bolusu. Ezinye iindlela zonyango (salicylic acid, podophyllin, urea, calcipotriol) nazo zifuna ukusetyenziswa rhoqo.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
Acanthosis nigricans (AN) is a common dermatologic manifestation of systemic disease that is associated with insulin resistance, diabetes mellitus, obesity, internal malignancy, endocrine disorders, and drug reactions. Treatment of AN primarily focuses on resolution of the underlying disease processes causing the velvety, hyperpigmented, hyperkeratotic plaques found on the skin. Initial considerations for the AN workup include evaluating patients for insulin resistance syndrome characterized by obesity, dyslipidemia, hypertension, and diabetes mellitus type II. For cosmetic treatment, topical retinoids are considered the first-line therapy for insulin-resistant AN by modifying keratinization rate. However, topical tretinoin requires application for long durations and improves hyperkeratosis, but not hyperpigmentation. Topical salicylic acid, podophyllin, urea, and calcipotriol also require frequent application, while TCA peels may provide a faster and less time-intense burden.
○ Izizathu
Ngokuqhelekileyo kwenzeka kubantu abangaphantsi kweminyaka engama‑40 ubudala, abanemfuzo kwaye inxulunyaniswa nokutyeba kakhulu okanye i‑endocrinopathies, njenge‑hypothyroidism, i‑acromegaly, isifo se‑poly‑cystic ovary, isifo seswekile esinganyangekiyo kwi‑insulin okanye isifo sika‑Cushing.
○ Unyango ― OTC Amachiza
#40% urea cream